Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

An estimated 3.4 million Brits meet the criteria to receive a prescription for Wegovy and Mounjaro which would cost ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Hengrui's GLP-1/GIP drug shows 22.8% weight loss at 36 weeks in Phase 2, beating Eli Lilly's retatrutide. Kailera ...

ITV viewers slammed the show for 'sending a dangerous message' and 'medical misinformation' after a guest, showcased her before and after pictures.